 The European Commission has approved a supply contract with U.S. firm Novavax, all the purchase of up to 200 million COVID-19 vaccines. The commission said under the contract, EU states will be able to purchase up to 100 million doses of the Novavax vaccine, with an option for 100 million additional doses until 2023, once the short has been approved by the EU drugs regulator. It said the deal will allow EU states to receive the first Novavax doses from the last quarter of this year.